Strategic Advocates’s Ginkgo Bioworks DNA Stock Holding History

Strategic Advocates’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.8K	Sell	6,737 -530	-7%	-$4.43K	0.26%	71
2026 Q1	$44.5K	Buy	7,267 +2,886	+66%	+$24K	0.2%	82
2025 Q4	$35.7K	Buy	4,381 +3,899	+809%	+$42K	0.01%	228
2025 Q3	$7.03K	Buy	+482	New	+$5.77K	﹤0.01%	381

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Strategic Advocates's DNA Position: Q2 2026 in Review

Strategic Advocates reduced its Ginkgo Bioworks (DNA) stake by 7.3% in Q2 2026, selling an estimated $4.43K and leaving 6,737 shares worth $66.8K. The position accounts for 0.26% of the portfolio, ranked #71.

Strategic Advocates first reported a position in DNA in Q3 2025 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Strategic Advocates held 6,737 shares of Ginkgo Bioworks worth $66.8K as of Q2 2026.
Strategic Advocates sold 530 Ginkgo Bioworks shares in Q2 2026, an estimated $4.43K.
Ginkgo Bioworks made up 0.26% of Strategic Advocates's portfolio in Q2 2026, its #71 holding.
Strategic Advocates first reported a position in Ginkgo Bioworks in Q3 2025 and has held it in 4 quarters since.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.